Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-03-20 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1480 characters) and contains an 'RNS Number' and mentions the 'London Stock Exchange'. The content describes a 'Price Monitoring Extension' related to auction call periods, which is a specific operational announcement related to trading mechanics, not a core financial report (like 10-K, IR, or ER). Since it is a regulatory announcement distributed via RNS and does not fit any of the specific financial or corporate action categories (like DIV, CAP, MANG), it falls best under the general regulatory announcement category, RNS.
2020-03-20 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled with an 'RNS Number' and contains the header 'Transaction by Person Discharging Managerial Responsibilities' under 'Disclosure under Article 19 of the EU Market Abuse Regulation'. It details a purchase of American Depositary Shares (ADSs) by a Non-Executive Director (Tony Mok). This type of insider transaction disclosure, especially when filed via RNS (Regulatory News Service), directly corresponds to the definition of Director's Dealing (DIRS). Although it is a regulatory filing, DIRS is a more specific category than the general RNS fallback.
2020-03-20 English
LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA
Foreign Filer Report
2020-03-19 English
Lynparza granted orphan drug designation in Japan
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7608G' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content is a press release announcing that Lynparza received orphan drug designation in Japan, detailing clinical trial results (POLO trial) and providing company/contact information. This format—a brief, timely announcement of a specific corporate event or regulatory update distributed via an official news service—is characteristic of a Regulatory News Service (RNS) announcement. Since it is a specific announcement and not a comprehensive report (like 10-K or IR), and it fits the description of a general regulatory announcement, the most appropriate code is RNS.
2020-03-19 English
IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE
Foreign Filer Report
2020-03-17 English
Imfinzi confirmed overall survival in CASPIAN
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 4182G' and is dated March 17, 2020. It contains an announcement regarding clinical trial results (CASPIAN trial for Imfinzi) and provides contact information for Media Relations and Investor Relations, concluding with a statement that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. This structure is characteristic of a regulatory news service announcement, which falls under the general category of 'Regulatory Filings' (RNS) when it doesn't fit a more specific category like ER, DIV, or DIRS. While it discusses clinical trial data, it is an announcement of the data, not a comprehensive financial report (10-K, IR) or a dedicated presentation (IP). Therefore, RNS is the most appropriate classification. FY 2020
2020-03-17 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.